Ergagin 0.125mg Injection
Marketer
Mercury Laboratories Ltd
Salt Composition
Methylergometrine (0.125mg)
Overview Ergagin 0.125mg Injection
Uterine hemorrhage following childbirth or termination of pregnancy may be managed with Ergagin 0.125mg Injection. This medication acts on uterine smooth muscle, enhancing contractile force, frequency, and intensity to minimize blood loss. Administered intravenously or intramuscularly by a physician in a hospital setting, Ergagin 0.125mg Injection is not for self-injection. Dosage and frequency are determined by your doctor based on your individual needs and condition. Treatment aims to alleviate symptoms; your physician will adjust the dosage accordingly. Headache, elevated blood pressure, and convulsions are potential side effects; notify your physician if these occur or worsen, as mitigation strategies may be available. Alcohol consumption should generally be avoided during treatment. Prior to commencing treatment, inform your doctor of any pre-existing heart conditions or hypertension, as well as all other medications you are currently using, since interactions may affect Ergagin's efficacy or mechanism of action.
Uses of Ergagin 0.125mg Injection
Hemorrhage postpartum
Major Benefits of Ergagin 0.125mg Injection:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
Common Side effects of Ergagin 0.125mg Injection:
- High blood pressure
- Headache
- Seizure
How to use Ergagin 0.125mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Ergagin 0.125mg Injection works:
Ergagin 0.125mg Injection, derived from ergot alkaloids, induces prolonged uterine smooth muscle contractions. This action constricts blood vessels, thereby managing postpartum hemorrhage.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The safety of alcohol consumption alongside Ergagin 0.125mg Injection is undetermined. Seek medical advice before combining them.
PregnancyUNSAFE
Administering Ergagin 0.125mg Injection to pregnant individuals poses a substantial risk. Pregnant women should consult their physician before use, as research in both animal and human subjects has revealed considerable adverse effects on fetal development.
Breast feedingCAUTION
The administration of Ergagin 0.125mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily suspended throughout the mother's treatment and until the medication is fully cleared from her system.
DrivingCONSULT YOUR DOCTOR
The effect of Ergagin 0.125mg Injection on driving ability is undetermined. Refrain from driving if you exhibit symptoms impairing concentration or reaction time.
KidneyCONSULT YOUR DOCTOR
Data on Ergagin 0.125mg Injection use in patients with renal impairment is scarce. Physician consultation is advised.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of 0.125mg Ergagin Injection to individuals with hepatic impairment. Physician consultation is recommended.
What if you forget to take Ergagin 0.125mg Injection :
NA
Facts to Know About Ergagin 0.125mg Injection
| Label | Value |
|---|---|
| Chemical Type | Ergoline alkaloids |
| Developing Habits | No. |
| Treatment Category | OBSTETRICS AND GYNECOLOGY |
| Action Class | Drugs that induce uterine contractions and abortion |
3,018 People bought this recently